糖蛋白质在肝癌中的临床诊断价值

Diagnostic value of glycoprotein in liver cancer

原发性肝癌是我国第4位常见恶性肿瘤及第2位肿瘤致死病因,研发新型生物标志物应用于肝癌患者的早诊早治对于提高生存率十分重要。目前临床上常见的肿瘤标志物大多是糖蛋白质,组学技术对于探索糖蛋白质在肝癌中的临床诊断价值具有重要作用。本文基于肿瘤临床诊断中的糖蛋白质标志物,分析了其诊断方法、问题与挑战;介绍针对糖蛋白质研究的相关技术,包括高通量组学和单一糖蛋白质检测方法,以及基于这些技术发现肝癌潜在的糖蛋白质标志物;并且展望糖蛋白质在肝癌临床诊断中的潜力与应用价值。

Primary liver cancer is the fourth most common malignant tumor and the second leading cause of tumor death in China.The development of novel biomarkers for early diagnosis and treatment of liver cancer patients is important to improve the survival rate.The most common tumor biomarkers in clinical practice are glycoproteins currently.With omics technologies,the clinically significant glycoproteomics and glycomics for liver cancer diagnosis are discovered.In this article,a variety of glycobiomarkers were summarized.Methods,problems and challenges for clinical detection are posed.The relevant techniques of glycoprotein research,including high-throughput omics method and single glycoprotein detection are discussed,as well as potential liver cancer glycoprotein markers based on these techniques.The potential application of the glycoproteins in the clinical diagnosis of liver cancer is also considered.